Search results | Grifols

Reports

Partnering Agreements with Grifols

This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years

Insights

Grifols

Grifols is a top pharmaceutical company based in Barcelona, Spain.

Grifols: Keeping the world’s blood supply pumping

Grifols is a Spanish global pharmaceutical company specialising in the supply of blood plasma products.

Grifols: M&A activity 2005-2014

Grifols, listed as a big pharma and big biotech company, has announced 4 M&A deals since 2005, with the lead deals being the acquisitions of Tacleris Pharmaceuticals.

Grifols: Partnering activity 2005-2013

Grifols, a global healthcare company, listed as big biotech and big pharma company aims to improve health and well-being of the people.

Grifols: Company profile

Grifols, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Leader in plasma protein therapies created through Grifols/Talecris combination

It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Stada: From co-operative pharmacy to generics/OTC giant

STADA is a major global pharmaceutical company offering generics and OTC products.

Novartis and Merck & co are to exchange businesses

Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc’s over-the-counter products unit in a deal that could boost earnings at both companies.

Novartis is capable of spending $4-6 billion in m&a

Swiss drugmaker Novartis can spend $4-6 billion per year on m&a to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.

Events

Sorry, your search returned no results.


Deals

Alkahest banks $37.5 million in Grifols pact

Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging

Grifols acquires Novartis’ diagnostic unit for $1.68 billion

Grifols Diagnostic Division acquires Novartis  transfusion diagnostics unit for $1.68 billion.

Grifols big pharma deals Aradigm in licensing and option agreement for Pulmaquin, Lipoquin and AERx

Grifols, a big pharma company, has entered pharma deals with Aradigm for licensing and options relating to Pulmaquin, Lipoquin and AERx.

Big pharma Grifols in $41.4 million equity purchase financing

Grifols, a big pharma company, has entered into a $41.4 million equity purchase financing deal with Aradigm.

Grifols to sell assets to clear way for Talecris takeover

Grifols and Talecris Biotherapeutics Holdings Corporation have signed a “Consent Agreement” with the Staff of the Bureau of Competition of the US Federal Trade Commission (FTC)

Grifols nabs Talecris in $3.4bn buyout deal

Spain’s Grifols has struck a $3.4 billion deal to buy Talecris Biotherapeutics, finally delivering a premium return for the investment groups that backed the Research Triangle Park, NC-based biotech. Read the Grifols / Talecris story at Reuters

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif